Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia
| Autor: | Noboru Fujino, Kenshi Hayashi, Tetsuo Konno, Masakazu Yamagishi, Hiroshi Mabuchi, Junji Kobayashi, Chiaki Nakanishi, Atsushi Nohara, Akihiro Inazu, Masa-aki Kawashiri, Hayato Tada, Tohru Noguchi, Mika Mori |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Heterozygote medicine.medical_specialty Familial hypercholesterolemia Hyperlipoproteinemia Type II chemistry.chemical_compound Ezetimibe Internal medicine Humans Medicine Rosuvastatin Prospective Studies Rosuvastatin Calcium Anion Exchange Resins Aged Aged 80 and over Coenzyme Q10 Sulfonamides Dose-Response Relationship Drug business.industry Cholesterol Anticholesteremic Agents Imidazoles Cholesterol LDL Middle Aged medicine.disease Fluorobenzenes Resins Synthetic Pyrimidines Treatment Outcome Endocrinology chemistry Azetidines Kexin Drug Therapy Combination Epichlorohydrin Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Follow-Up Studies Lipoprotein medicine.drug |
| Zdroj: | The American Journal of Cardiology. 109:364-369 |
| ISSN: | 0002-9149 |
| Popis: | Aggressive low-density lipoprotein (LDL) cholesterol-lowering therapy is important for high-risk patients. However, sparse data exist on the impact of combined aggressive LDL cholesterol-lowering therapy in familial hypercholesterolemia (FH), particularly on side effects to changes in plasma coenzyme Q10 and proprotein convertase subtilisin/kexin type 9 levels. We enrolled 17 Japanese patients with heterozygous FH (12 men, 63.9 ± 7.4 years old) with single LDL receptor gene mutations in a prospective open randomized study. Permitted maximum doses of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day) were introduced sequentially. Serum levels of LDL cholesterol decreased significantly by -66.4% (p0.001) and 44% of participants achieved LDL cholesterol levels100 mg/dl. There were no serious side effects or abnormal laboratory data that would have required the protocol to have been terminated except for 1 patient with myalgia. Coadministration of ezetimibe and granulated colestimide further lowered serum LDL cholesterol more than rosuvastatin alone without changing plasma coenzyme Q10 and proprotein convertase subtilisin/kexin type 9 levels. In conclusion, adequate introduction of this aggressive cholesterol-lowering regimen can improve the lipid profile of FH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect